Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with ¹⁷⁷Lu-PSMA and Combined ²²⁵Ac- and ¹⁷⁷Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xerostomia and becomes dose-limiting for <sup>2...

詳細記述

書誌詳細

出版年:	Diagnostics
主要な著者:	Thomas Langbein, Harshad R. Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk, Richard P. Baum
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2022-08-01
主題:	PSMA radioligand therapy mCRPC salivary gland toxicity xerostomia
オンライン･アクセス:	https://www.mdpi.com/2075-4418/12/8/1926